drugset / Trial / NCT04218734
A Study of DBPR108 and Metformin Hydrochloride Combination Therapy in Patients With T2DM
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study aims to evaluate the efficacy and safety of DBPR108 tablets in combination with metformin hydrochloride in the treatment of type 2 diabetes mellitus. A total of 210 subjects will be randomly assigned in a ratio of 2:1 to receive metformin hydrochloride plus DBPR108 or metformin hydrochloride plus placebo.
Timeline
- Start
- 2020-01-14
- Primary completion
- 2021-06-03
- Completion
- 2021-06-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DBPR108 | Small molecule | 100 mg | — |
| Background | Metformin | Small molecule | 500 mg | — |